Biocon Limited · NSE:BIOCON

Biocon — Q1 FY24 Earnings Presentation

21 slides from Biocon's earnings presentation, Aug 11, 2023

  1. Slide 1: Q1 FY24 Earnings Call

    Q1 FY24 Earnings Call August 11, 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s

  3. Slide 3: Opening Remarks

    Opening Remarks

  4. Slide 4: Biocon Generics: Strategic Growth Pillar

    Biocon Generics: Strategic Growth Pillar Execution Excellence Development Operational Quality Commercial Excellence Excellence Excellence Excellence Cost Innovation Talent Digital Leadership Focus Development Initiatives

  5. Slide 5: Biocon Biologics: Biosimilars – Strategic Growth Pillar

    Biocon Biologics: Biosimilars – Strategic Growth Pillar Portfolio Depth & Breadth Operational and organizational integration of acquired business in FY24 Excellence in R&D Tracking ahead of Plan vs. a 2-year Cost-Effective Manufacturing Transition Services Agreement Global Quality Standards 70+ coun

  6. Slide 6: Syngene: Strategic Growth Pillar

    Syngene: Strategic Growth Pillar Discovery Services Dedicated R&D Centers Development Services Manufacturing Services

  7. Slide 7: Progressed to Integrated Reporting

    Progressed to Integrated Reporting Continuously improving disclosures towards better transparency 1st GRI aligned Integrated Report for FY23 with many maiden disclosures Outcome of Gender Pay Gap Analysis Alignment with TCFD Outcome of Water Risk Assessment Outcome of Biodiversity Impact Assessment

  8. Slide 8: Board Update

    £ © Oo Q =) o i © fe} aa)

  9. Slide 9: Board Appointments

    Board Appointments Rekha Mehrotra Menon Nicolas Robert Haggar Appointed as Additional Independent Director Appointed as Additional Independent Director

  10. Slide 10: Financial Highlights Q1 FY24

    Financial Highlights Q1 FY24

  11. Slide 11: Financial Highlights: Q1 FY24

    Financial Highlights: Q1 FY24 Consolidated (in ₹ Cr.) Q1 FY24 Q1 FY23 YoY % Total Revenue 3,516 2,217 59 Biosimilars +106% | Research +25% | Generics 15% Core EBITDA1 936 661 42 Growth across Generics, Biosimilars & Research Services % Margin 28% 31% Net R&D spend at ₹315 Cr, up ₹117 Cr vs Q1 FY23,

  12. Slide 12: Generics Q1 FY24

    Generics Q1 FY24

  13. Slide 13: Biocon Generics: Q1 FY24 Highlights

    Biocon Generics: Q1 FY24 Highlights Revenue growth driven primarily by U.S. generic formulations business; new product launches in key ex-US markets In INR Cr Q1 FY24 Q1 FY23 YoY % Continued traction in immunosuppressant API portfolio Segment Revenue 700 607 15 PBT 64 63 1 Received ‘Tentative Approv

  14. Slide 14: Biosimilars Q1 FY24

    Biosimilars Q1 FY24

  15. Slide 15: Biocon Biologics: Biosimilars – Q1 FY24 Business Update

    Biocon Biologics: Biosimilars – Q1 FY24 Business Update Key Products’ Market Share1 Significant growth in market shares of key commercial products United States Jun-23 Jun-22 Fulphila (bPegfilgrastim) 16% 8% Increase in NRx to 15% for Insulin Glargine in the U.S., demonstrates Ogivri (bTrastuzumab)

  16. Slide 16: Biocon Biologics: Biosimilars – Q1 FY24 Financial Update

    Biocon Biologics: Biosimilars – Q1 FY24 Financial Update Revenues doubled Y-o-Y with driven by increased market share and In INR Cr Q1 FY24 Q1 FY23 YoY % consolidation of Viatris’ biosimilar business Revenue 2,015 977 106 Core EBITDA1 513 361 42 Sequentially, revenues largely flat due to phasing of

  17. Slide 17: Biocon Biologics: Biosimilars – Q1 FY24 Other Updates

    Biocon Biologics: Biosimilars – Q1 FY24 Other Updates Growth Catalysts Yesafili (bAflibercept) received positive opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use Growth in existing business Clinical trials for bUstekinumab and bDenosumab on track Expanded geogr

  18. Slide 18: Research Services Q1 FY24

    Research Services Q1 FY24 Syngene

  19. Slide 19: Syngene: Q1 FY24 Update

    Syngene: Q1 FY24 Update Strong performance led by Development and Manufacturing Services; supported by sustained growth in Discovery Services and the Dedicated In INR Cr Q1 FY24 Q1 FY23 YoY % Centers Revenue 808 645 25 Announced deal to acquire multimodal biologics plant from Stelis along with PBT 1

  20. Slide 20: Concluding Remarks

    Concluding Remarks

  21. Slide 21: Q&A

    Q&A

Biocon — Q1 FY24 Earnings Presentation on 6ix